X0306 4 2018-03-19 0 0001314102 pSivida Corp. PSDV 0001458753 Ross Leonard S C/O PSIVIDA CORP. 480 PLEASANT STREET WATERTOWN MA 02472 0 1 0 0 See Remarks Common stock 2018-03-19 4 A 0 10000 0.00 A 10000 D On March 19, 2018 (the "NDA Acceptance Date"), the U.S. Food and Drug Administration ("FDA") accepted pSivida Corp.'s (the "Company") new drug application for Durasert 3-year treatment for posterior segment uveitis. As a result, 5,000 shares representing a previously granted performance stock unit award vested on that date. An additional 5,000 shares from this award will vest on the first anniversary of the NDA Acceptance Date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date. Vice President of Finance and Chief Accounting Officer /s/ John Mercer, Attorney-in-Fact 2018-03-21